Trial to Evaluate Efficacy and Safety of LIB003 and Inclisiran in High-risk CVD Patients
Status:
Not yet recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
Comparison of LDL-C reductions of lerodalcibep (LIB003) 300 mg to inclisiran (Leqvio®) 284 in
patients at very-high risk or high-risk for CVD on stable diet and oral LDL-C-lowering drug
therapy